S
Shanthi Sivendran
Researcher at Icahn School of Medicine at Mount Sinai
Publications - 22
Citations - 500
Shanthi Sivendran is an academic researcher from Icahn School of Medicine at Mount Sinai. The author has contributed to research in topics: Clinical trial & Consolidated Standards of Reporting Trials. The author has an hindex of 10, co-authored 19 publications receiving 442 citations.
Papers
More filters
Journal ArticleDOI
Adverse Event Reporting in Cancer Clinical Trial Publications
Shanthi Sivendran,Asma Latif,Russell B. McBride,Kristian D. Stensland,Juan P. Wisnivesky,Lindsay Haines,William Oh,Matthew D. Galsky +7 more
TL;DR: Reporting of adverse events in oncology publications of randomized trials is suboptimal and characterized by substantial selectivity and heterogeneity, which should be established to ensure consistency and provide critical information required for medical decision-making.
Journal ArticleDOI
Metabolic complications with the use of mTOR inhibitors for cancer therapy
Shanthi Sivendran,Neeraj Agarwal,Neeraj Agarwal,Benjamin A. Gartrell,Jian Ying,Kenneth M. Boucher,Toni K. Choueiri,Guru Sonpavde,William Oh,Matthew D. Galsky +9 more
TL;DR: The findings suggest a statistically significant increase in the risk of hyperglycemia, hypercholesterolemia (all grades and grade 3 and 4), and all grade hypertriglyceridemia associated with mTOR therapy when compared with control.
Journal ArticleDOI
Oncolytic virus therapy for cancer
Joe Goldufsky,Shanthi Sivendran,Sara Harcharik,Michael Pan,Sebastian Bernardo,Richard H Stern,Philip Friedlander,Carl E. Ruby,Yvonne Saenger,Howard L. Kaufman +9 more
TL;DR: There are increasing data demonstrating the potential promise of this approach for the treatment of human and animal cancers, and current strategies to optimize the therapeutic effectiveness and safety of the major oncolytic viruses are discussed.
Journal ArticleDOI
Treatment-related mortality with vascular endothelial growth factor receptor tyrosine kinase inhibitor therapy in patients with advanced solid tumors: A meta-analysis
Shanthi Sivendran,Ziyue Liu,Louis J. Portas,Menggang Yu,Noah M. Hahn,Guru Sonpavde,William Oh,Matthew D. Galsky +7 more
TL;DR: This analysis suggests that VEGFR TKIs are associated with a significant increase in the risk of FAEs in patients with advanced solid tumors.
Journal ArticleDOI
Dissection of Immune Gene Networks in Primary Melanoma Tumors Critical for Antitumor Surveillance of Patients with Stage II–III Resectable Disease
Shanthi Sivendran,Rui Chang,Lisa Pham,Robert G. Phelps,Sara Harcharik,Lawrence D. Hall,Sebastian Bernardo,Marina Moskalenko,Meera Sivendran,Yichun Fu,Ellen H de Moll,Michael Pan,Jee-Young Moon,Sonali Arora,Ariella Cohain,Analisa DiFeo,Tammie Ferringer,Mikhail Tismenetsky,Mikhail Tismenetsky,Cindy L. Tsui,Philip Friedlander,Michael K. Parides,Jacques Banchereau,Damien Chaussabel,Mark Lebwohl,Jedd D. Wolchok,Nina Bhardwaj,Nina Bhardwaj,Steven J. Burakoff,William Oh,Karolina Palucka,Karolina Palucka,Miriam Merad,Eric E. Schadt,Yvonne Saenger +34 more
TL;DR: The identified driver genes are potential therapeutic targets, and the 53-gene panel should be tested for clinical application using a larger data set annotated on the basis of prospectively gathered data.